NCT05572463 - A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma | Biotech Hunter

Timeline

Start Date

November 1, 2022

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions

Unresectable Cutaneous MelanomaMetastatic Cutaneous Melanoma

Interventions

COMBINATION_PRODUCT

Sintilimab + IBI110

IBI110 infusion in combination with Sintilimab (IBI308) infusion will be given on a Q3W schedule

Trial Locations (13)

Princess Victoria Hospital, Woolloongabba

Universitaets Spital Zurich, Zurich

Institut Catala d'Oncologia Hospital Universitari Germans Trials I Pujol, Barcelona, Barcelona

Hospital Universitario Reina Sofia, Cordoba, Córdoba

Universitatsklinikum Essen, Essen

Henry Ford Hospital, Detroit

Hospices Civil De Lyon Nord - Centre Hospitalier Lyon Sud - Dermatologie, Lyon

Hospital Saint Louis, Paris

University of California San Francisco Medical Center, San Francisco

Hackensack University Medical Center, Hackensack

Universitatsklinikum Carl Gustav Carus, Dresden

Cambridge University Hospitals NHS Foundation Trust (Oxford), Cambridge

Lancashire Teaching Hospitals (Preston), Preston